Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-30

FDA Approved: VYXEOS — Supplemental Application (Jazz Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for VYXEOS (daunorubicin and cytarabine liposome) from Jazz Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vyxeos (CPX-351)

Snippet

SUPPL AP for VYXEOS ((DAUNORUBICIN AND CYTARABINE) LIPOSOME)